-
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer's drug
Federal regulators are putting off a decision on Eli Lilly’s potential Alzheimer’s treatment with an unusual request to have an advisory committee examine the drug. Lilly expected a decision on donanemab in this year’s first quarter, which ends this month.
-
Biogen will stop selling its controversial Alzheimer's drug Aduhelm
Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential blockbuster but it stumbled after its launch a few years ago.
-
‘Only one who didn't have gray hair:' Alzheimer's effect on the young — and their even younger caregivers
Researcher’s say there’s been an alarming increase among adults in their 40s and 50s who have been diagnosed with Alzheimer’s disease. That has ripple effects on the family members of those younger patients, who often fill caregiving roles.
-
One Northern Virginia family's journey with early-onset Alzheimer's disease
Alzheimer’s is not just a disease of old age, as two sisters in Northern Virginia learned when their mom was diagnosed at age 51. News4’s Eun Yang reports.
-
Study examines if 4 lifestyle changes can prevent or reverse Alzheimer's
Doctors are testing if four lifestyle changes can slow, stop — or even reverse — Alzheimer’s disease without using drugs or surgery.
-
Study eyes whether lifestyle changes can prevent Alzheimer's
Doctors are looking at four key lifestyle changes that may prevent or reverse Alzheimer’s disease. “To reduce it to its essence: eat well, move more, stress less and love more,” Dr. Dean Ornish said. News4’s Jummy Olabanji reports.
-
After US approval, Japan approves Leqembi, its first Alzheimer's drug
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
-
Campaign aims to raise Alzheimer's awareness in Hispanic communities
Latinos are 1.5 times more likely to develop Alzheimer’s than other races, according to the Alzheimer’s Association.
-
10 possible signs of Alzheimer's — and how the disease affects Hispanic people
The Alzheimer’s Association created a list of early signs of the disease or other types of dementia. In the United States, the disease disproportionately affects Hispanic patients.
-
Bob Barker died from Alzheimer's disease, death certificate states
Barker died at age 99 from Alzheimer’s disease and other contributing factors, as outlined in his death certificate.
-
Some insurers won't cover new Alzheimer's treatment shown to slow decline
Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.
-
Study shows Eli Lilly's Alzheimer's drug slows memory decline but with safety risks
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding.
-
FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
-
Alzheimer's drug gets FDA panel's backing, setting the stage for broader use
U.S. health advisers are backing the full approval of an Alzheimer’s drug that received preliminary approval last year. A panel of advisers to the Food and Drug Administration on Friday voted in favor of the infused medication from drugmakers Eisai and Biogen. The FDA granted accelerated approval in January based on early results suggesting the drug could modestly slow Alzheimer’s....
-
Medicare Details Plan to Cover Alzheimer's Treatments
Patients will have to participate in registries that collect real-world data on how the drug works as a condition of coverage.
-
Experimental Drug Slows Worsening Effects of Alzheimer's
Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5’s Bianca Castro talked with Frisco neurologist Dr. Aimee Garza about how it works.
-
Eli Lilly Says Experimental Drug Slows Alzheimer's Worsening
Eli Lilly and Co. says its experimental Alzheimer’s drug appears to slow worsening of the mind-robbing disease after an 18-month trial.
-
Alzheimer's: Medicare Will Cover Leqembi for All Patients If FDA Approves Drug, CMS Chief Says
Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.
-
Eli Lilly Says Experimental Alzheimer's Drug Reduces Brain Plaque in Early Study
Eli Lilly said a higher dose of the up-and-coming Alzheimer’s treatment remternetug had a larger effect on clearing amyloid plaque.
-
Alzheimer's ‘Escapees': Scientists Seek Clues From Those Who Evade Genetic Fate
Scientists are digging into why a few people escape the rarest form of Alzheimer’s, which is inherited and strikes young. Every so often, someone dodges their family’s genetic fate.